Prolonged Survival Using First-Line Pazopanib in a Filipino Male with Renal Cell Carcinoma and Brain Metastasis: A Case Report

Renal cell carcinoma is one of the leading causes of cancer worldwide. Brain metastasis is a poor prognostic factor among patients with this disease. The advancements in understanding of the molecular framework behind malignancy and brain metastasis led to more sophisticated treatment regimens which...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christianne V. Mojica, Gerard Vincent A. Aguas, Gerardo Thomas H. Cornelio, Ludwig F. Damian
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	brain metastasis pazopanib tyrosine kinase inhibitor renal cell carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/fcab449b558a40d2a792087ebcf71d57
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fcab449b558a40d2a792087ebcf71d57
record_format	dspace
spelling	oai:doaj.org-article:fcab449b558a40d2a792087ebcf71d572021-11-18T11:08:46ZProlonged Survival Using First-Line Pazopanib in a Filipino Male with Renal Cell Carcinoma and Brain Metastasis: A Case Report1662-657510.1159/000519745https://doaj.org/article/fcab449b558a40d2a792087ebcf71d572021-10-01T00:00:00Zhttps://www.karger.com/Article/FullText/519745https://doaj.org/toc/1662-6575Renal cell carcinoma is one of the leading causes of cancer worldwide. Brain metastasis is a poor prognostic factor among patients with this disease. The advancements in understanding of the molecular framework behind malignancy and brain metastasis led to more sophisticated treatment regimens which include targeted drugs and immunotherapy. While the role of tyrosine kinase inhibitors in metastatic renal cell carcinoma has been proven in the literature, its specific role among patients with brain metastasis has not yet been fully elucidated. We report a case of a Filipino male with renal cell carcinoma and brain metastasis who underwent stereotactic radiosurgery of his right frontal lesion followed by pazopanib taken initially at 800 mg/day and then decreased to 600 mg/day. A significant increase in creatinine level led to the discontinuation of the medication after >3 years. He had a remarkable progression-free survival of 38 months. This is the first documented case of such significant response to pazopanib in a patient with renal cell carcinoma and brain metastasis. In the Philippine setting where options for cancer treatment are limited by the prohibitive cost of medications, this case can support the use of pazopanib as a potent agent for treating patients with this condition.Christianne V. MojicaGerard Vincent A. AguasGerardo Thomas H. CornelioLudwig F. DamianKarger Publishersarticlebrain metastasispazopanibtyrosine kinase inhibitorrenal cell carcinomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCase Reports in Oncology, Vol 14, Iss 3, Pp 1516-1521 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	brain metastasis pazopanib tyrosine kinase inhibitor renal cell carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	brain metastasis pazopanib tyrosine kinase inhibitor renal cell carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Christianne V. Mojica Gerard Vincent A. Aguas Gerardo Thomas H. Cornelio Ludwig F. Damian Prolonged Survival Using First-Line Pazopanib in a Filipino Male with Renal Cell Carcinoma and Brain Metastasis: A Case Report
description	Renal cell carcinoma is one of the leading causes of cancer worldwide. Brain metastasis is a poor prognostic factor among patients with this disease. The advancements in understanding of the molecular framework behind malignancy and brain metastasis led to more sophisticated treatment regimens which include targeted drugs and immunotherapy. While the role of tyrosine kinase inhibitors in metastatic renal cell carcinoma has been proven in the literature, its specific role among patients with brain metastasis has not yet been fully elucidated. We report a case of a Filipino male with renal cell carcinoma and brain metastasis who underwent stereotactic radiosurgery of his right frontal lesion followed by pazopanib taken initially at 800 mg/day and then decreased to 600 mg/day. A significant increase in creatinine level led to the discontinuation of the medication after >3 years. He had a remarkable progression-free survival of 38 months. This is the first documented case of such significant response to pazopanib in a patient with renal cell carcinoma and brain metastasis. In the Philippine setting where options for cancer treatment are limited by the prohibitive cost of medications, this case can support the use of pazopanib as a potent agent for treating patients with this condition.
format	article
author	Christianne V. Mojica Gerard Vincent A. Aguas Gerardo Thomas H. Cornelio Ludwig F. Damian
author_facet	Christianne V. Mojica Gerard Vincent A. Aguas Gerardo Thomas H. Cornelio Ludwig F. Damian
author_sort	Christianne V. Mojica
title	Prolonged Survival Using First-Line Pazopanib in a Filipino Male with Renal Cell Carcinoma and Brain Metastasis: A Case Report
title_short	Prolonged Survival Using First-Line Pazopanib in a Filipino Male with Renal Cell Carcinoma and Brain Metastasis: A Case Report
title_full	Prolonged Survival Using First-Line Pazopanib in a Filipino Male with Renal Cell Carcinoma and Brain Metastasis: A Case Report
title_fullStr	Prolonged Survival Using First-Line Pazopanib in a Filipino Male with Renal Cell Carcinoma and Brain Metastasis: A Case Report
title_full_unstemmed	Prolonged Survival Using First-Line Pazopanib in a Filipino Male with Renal Cell Carcinoma and Brain Metastasis: A Case Report
title_sort	prolonged survival using first-line pazopanib in a filipino male with renal cell carcinoma and brain metastasis: a case report
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/fcab449b558a40d2a792087ebcf71d57
work_keys_str_mv	AT christiannevmojica prolongedsurvivalusingfirstlinepazopanibinafilipinomalewithrenalcellcarcinomaandbrainmetastasisacasereport AT gerardvincentaaguas prolongedsurvivalusingfirstlinepazopanibinafilipinomalewithrenalcellcarcinomaandbrainmetastasisacasereport AT gerardothomashcornelio prolongedsurvivalusingfirstlinepazopanibinafilipinomalewithrenalcellcarcinomaandbrainmetastasisacasereport AT ludwigfdamian prolongedsurvivalusingfirstlinepazopanibinafilipinomalewithrenalcellcarcinomaandbrainmetastasisacasereport
_version_	1718420882255249408

Prolonged Survival Using First-Line Pazopanib in a Filipino Male with Renal Cell Carcinoma and Brain Metastasis: A Case Report

Ejemplares similares